Tidal Investments LLC Has $1.94 Million Stake in Glaukos Co. (NYSE:GKOS)

Tidal Investments LLC boosted its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 83.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,908 shares of the medical instruments supplier's stock after purchasing an additional 6,767 shares during the period. Tidal Investments LLC's holdings in Glaukos were worth $1,942,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GKOS. Values First Advisors Inc. acquired a new position in shares of Glaukos in the 3rd quarter worth approximately $25,000. Harvest Fund Management Co. Ltd raised its position in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock valued at $117,000 after purchasing an additional 860 shares during the last quarter. KBC Group NV boosted its stake in Glaukos by 16.2% in the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock worth $188,000 after purchasing an additional 201 shares in the last quarter. EWA LLC bought a new stake in shares of Glaukos during the third quarter worth $209,000. Finally, Fifth Third Wealth Advisors LLC acquired a new stake in shares of Glaukos in the second quarter valued at $187,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on GKOS. Piper Sandler set a $140.00 price objective on shares of Glaukos in a report on Thursday, October 17th. BTIG Research increased their price target on shares of Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Stephens raised shares of Glaukos to a "strong-buy" rating in a report on Monday, December 2nd. StockNews.com raised Glaukos from a "sell" rating to a "hold" rating in a report on Monday, October 21st. Finally, UBS Group started coverage on Glaukos in a research note on Friday, December 6th. They issued a "buy" rating and a $182.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $143.17.

Insiders Place Their Bets

In related news, COO Joseph E. Gilliam sold 2,275 shares of the company's stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at approximately $14,198,425.93. This represents a 2.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total value of $288,020.00. Following the completion of the sale, the director now directly owns 32,336 shares in the company, valued at $4,656,707.36. This represents a 5.82 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.

Glaukos Trading Up 1.5 %

Shares of GKOS stock traded up $2.22 on Tuesday, reaching $146.35. The company had a trading volume of 703,556 shares, compared to its average volume of 570,555. The stock has a market cap of $8.07 billion, a PE ratio of -48.46 and a beta of 1.03. The company has a 50-day moving average of $136.61 and a 200-day moving average of $127.28. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12 month low of $74.75 and a 12 month high of $147.65.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. The firm had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business's quarterly revenue was up 23.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.50) earnings per share. On average, equities analysts forecast that Glaukos Co. will post -1.89 earnings per share for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.